Poster presentation | Open | Published:
Effect of HO-3089 PARP inhibitor on inflammatory response
Critical Carevolume 15, Article number: P252 (2011)
The activation of poly-ADP-ribose-polymerase enzyme (PARP) plays an important role in the pathophysiology of sepsis . In previous animal models, lipopolysaccharide-induced systemic inflammatory response was significantly reduced by the inhibition of PARP . The aim of our study was to investigate the effect of PARP inhibition on systemic inflammation in a septic animal model.
In a prospective, randomized study, anaesthetized CFY rats were divided into four groups (five/group): cecal ligation group (CL), cecal ligation and punction group (CLP), CLP with PARP inhibition (CLP+Pi) group and sham group. PARP inhibition was performed by HO-3089 (a novel PARP inhibitor) given intraperitoneally (10 mg/kg). Heart rate, invasive blood pressure and the rectal temperature were monitored. Data were recorded every 15 minutes. To identify the inflammatory response, IL-6 and TNFα were measured by quantitative sandwich enzyme immunoassay technique. Blood samples were taken before the CLP (t0), 2 hours (t1) and 6 hours (t2) after the CLP.
IL-6 and TNFα were significantly higher in the CLP and CLP+Pi groups at t2 as compared with t0 (CLP: PIL-6 < 0.001, PTNFα < 0.001; CLP+Pi:PIL-6 = 0.002, PTNFα < 0.001), and also as compared with the CL and sham groups at t2 (CL vs. CLP: PIL-6 < 0.001, PTNFα = 0.002; CL vs. CLP+Pi: PIL-6 = 0.008, PTNFα = 0.002; sham vs. CLP: pIL-6 < 0.001, PTNFα = 0.002; sham vs. CLP+Pi: PIL-6 = 0.011, PTNFα = 0.002). Although in the CLP+Pi group theIL-6 level was lower than in the CLP group at t2, but the difference was not significant (P = 0.074). There was no significant difference in TNFα between the CLP and CLP+Pi groups either.
The initial results of this study could not show a significant effect of the HO-3089 PARP inhibitor in CLP caused systemic inflammatory response. However, the tendency of lower IL-6 in the treated group warrants the completion of the experiment.
Lobo SM, et al.: J Surg Res. 2005, 129: 292-297. 10.1016/j.jss.2005.05.018
Veres B, et al.: Biochem Pharmacol. 2003, 65: 1373-1382. 10.1016/S0006-2952(03)00077-7